LSL Pharma Group Inc

As of June 30, 2026, LSL Pharma Group Inc carries a market capitalization of 39.29M, placing it among publicly traded companies globally. Its enterprise value stands at 88.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

LSL Pharma Group Inc's next confirmed earnings release is scheduled for December 1, 2026.

As of June 30, 2026, LSL Pharma Group Inc has 126.73M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.92, and the price-to-book ratio stands at 1.79.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 88.91M versus a market cap of 39.29M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, LSL Pharma Group Inc maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 230.22, indicating elevated leverage, while an interest coverage ratio of -0.11 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, LSL Pharma Group Inc posted a negative return on equity (ROE) of -31.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.85, reflecting losses generated across the asset base. Inventory turnover of 2.61 indicates how many times LSL Pharma Group Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 24, 2026, LSL Pharma Group Inc's stock has declined approximately 15.79% over the past 52 weeks.

Over the twelve months ended June 30, 2026, LSL Pharma Group Inc generated 41.83M in revenue and converted that into -7.33M in net income, yielding earnings per share of -0.06. EBITDA reached -403,000.00, while operating income came in at -5.98M.

As of June 30, 2026, LSL Pharma Group Inc holds 967,000.00 in cash and equivalents against 50.59M in total debt, resulting in a net debt position of 36.20M. Total book value stands at 21.98M, with working capital of 3.68M providing operational flexibility.

LSL Pharma Group Inc produced -5.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.50M in capital expenditures, free cash flow totaled -11.36M - equivalent to -0.09 per share.

Over the twelve months ended June 30, 2026, LSL Pharma Group Inc posted a gross margin of 8.26, reflecting its pricing power and cost economics. The operating margin of -14.31 and net profit margin of -17.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, LSL Pharma Group Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -29.44: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.09, meaning LSL Pharma Group Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

LSL Pharma Group Inc's most recent stock split took place on March 1, 2023 with a 25:1 split ratio.

As of June 30, 2026, LSL Pharma Group Inc has an Altman Z-Score of 0.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.